JP2005533803A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533803A5 JP2005533803A5 JP2004515328A JP2004515328A JP2005533803A5 JP 2005533803 A5 JP2005533803 A5 JP 2005533803A5 JP 2004515328 A JP2004515328 A JP 2004515328A JP 2004515328 A JP2004515328 A JP 2004515328A JP 2005533803 A5 JP2005533803 A5 JP 2005533803A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- carbonitrile
- alkyl
- chlorophenyl
- morpholin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 229910052739 hydrogen Inorganic materials 0.000 claims description 41
- 239000001257 hydrogen Substances 0.000 claims description 38
- -1 amino, hydroxy Chemical group 0.000 claims description 29
- 229910052760 oxygen Inorganic materials 0.000 claims description 29
- 229910052717 sulfur Inorganic materials 0.000 claims description 29
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 229920006395 saturated elastomer Polymers 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 108090000613 Cathepsin S Proteins 0.000 claims description 2
- 102100035654 Cathepsin S Human genes 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 241001024304 Mino Species 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- HRXPLNARFGLXAV-UHFFFAOYSA-N 1-(4-cyano-6-morpholin-4-yl-1,3,5-triazin-2-yl)-n,n-diethylpiperidine-3-carboxamide Chemical compound C1C(C(=O)N(CC)CC)CCCN1C1=NC(C#N)=NC(N2CCOCC2)=N1 HRXPLNARFGLXAV-UHFFFAOYSA-N 0.000 claims 1
- CMRHBNMOCLQRSF-UHFFFAOYSA-N 4-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile Chemical compound N=1C(C#N)=NC(NC=2C=C3OCCOC3=CC=2)=NC=1N1CCOCC1 CMRHBNMOCLQRSF-UHFFFAOYSA-N 0.000 claims 1
- XWCQLQFUUUVLRU-UHFFFAOYSA-N 4-(4-aminopiperidin-1-yl)-6-(4-chloroanilino)-5-methoxypyrimidine-2-carbonitrile Chemical compound N1=C(C#N)N=C(N2CCC(N)CC2)C(OC)=C1NC1=CC=C(Cl)C=C1 XWCQLQFUUUVLRU-UHFFFAOYSA-N 0.000 claims 1
- YPDSLCXUIXJXNJ-UHFFFAOYSA-N 4-(4-aminopiperidin-1-yl)-6-(4-chloroanilino)pyrimidine-2-carbonitrile Chemical compound C1CC(N)CCN1C1=CC(NC=2C=CC(Cl)=CC=2)=NC(C#N)=N1 YPDSLCXUIXJXNJ-UHFFFAOYSA-N 0.000 claims 1
- NMABGHZGYRXDKI-UHFFFAOYSA-N 4-(4-chloroanilino)-5-methoxy-6-(3-oxopiperazin-1-yl)pyrimidine-2-carbonitrile Chemical compound N1=C(C#N)N=C(N2CC(=O)NCC2)C(OC)=C1NC1=CC=C(Cl)C=C1 NMABGHZGYRXDKI-UHFFFAOYSA-N 0.000 claims 1
- BTZKIHBFNQJXTB-UHFFFAOYSA-N 4-(4-chloroanilino)-5-methoxy-6-morpholin-4-ylpyrimidine-2-carbonitrile Chemical compound N1=C(C#N)N=C(N2CCOCC2)C(OC)=C1NC1=CC=C(Cl)C=C1 BTZKIHBFNQJXTB-UHFFFAOYSA-N 0.000 claims 1
- WUUXAWFBPPBXII-UHFFFAOYSA-N 4-(4-chloroanilino)-5-methoxy-6-piperazin-1-ylpyrimidine-2-carbonitrile Chemical compound N1=C(C#N)N=C(N2CCNCC2)C(OC)=C1NC1=CC=C(Cl)C=C1 WUUXAWFBPPBXII-UHFFFAOYSA-N 0.000 claims 1
- PQVMVGGJDJIQEL-UHFFFAOYSA-N 4-(4-chloroanilino)-6-(2-piperidin-1-ylethylamino)-1,3,5-triazine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC1=NC(NCCN2CCCCC2)=NC(C#N)=N1 PQVMVGGJDJIQEL-UHFFFAOYSA-N 0.000 claims 1
- ZPTOAFOTEBXFRX-UHFFFAOYSA-N 4-(4-chloroanilino)-6-(3-hydroxypyrrolidin-1-yl)-1,3,5-triazine-2-carbonitrile Chemical compound C1C(O)CCN1C1=NC(NC=2C=CC(Cl)=CC=2)=NC(C#N)=N1 ZPTOAFOTEBXFRX-UHFFFAOYSA-N 0.000 claims 1
- LNLMQGVSOHPCFR-UHFFFAOYSA-N 4-(4-chloroanilino)-6-(3-pyrrolidin-1-ylpropylamino)pyrimidine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC1=CC(NCCCN2CCCC2)=NC(C#N)=N1 LNLMQGVSOHPCFR-UHFFFAOYSA-N 0.000 claims 1
- XFOOFOWYROOZEA-UHFFFAOYSA-N 4-(4-chloroanilino)-6-(4-methylpiperazin-1-yl)-1,3,5-triazine-2-carbonitrile Chemical compound C1CN(C)CCN1C1=NC(NC=2C=CC(Cl)=CC=2)=NC(C#N)=N1 XFOOFOWYROOZEA-UHFFFAOYSA-N 0.000 claims 1
- XJKDWNYTZZEYQD-UHFFFAOYSA-N 4-(4-chloroanilino)-6-(4-phenylpiperidin-1-yl)-1,3,5-triazine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC1=NC(C#N)=NC(N2CCC(CC2)C=2C=CC=CC=2)=N1 XJKDWNYTZZEYQD-UHFFFAOYSA-N 0.000 claims 1
- BBAKVKGWOAPQKH-UHFFFAOYSA-N 4-(4-chloroanilino)-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyrimidine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC1=CC(N2CCC(CC2)N2CCCC2)=NC(C#N)=N1 BBAKVKGWOAPQKH-UHFFFAOYSA-N 0.000 claims 1
- NMWMRLWGNJUBRC-UHFFFAOYSA-N 4-(4-chloroanilino)-6-(dimethylamino)-1,3,5-triazine-2-carbonitrile Chemical compound N#CC1=NC(N(C)C)=NC(NC=2C=CC(Cl)=CC=2)=N1 NMWMRLWGNJUBRC-UHFFFAOYSA-N 0.000 claims 1
- FKNPVHLJQRYZPP-UHFFFAOYSA-N 4-(4-chloroanilino)-6-(dimethylamino)-5-methoxypyrimidine-2-carbonitrile Chemical compound N1=C(C#N)N=C(N(C)C)C(OC)=C1NC1=CC=C(Cl)C=C1 FKNPVHLJQRYZPP-UHFFFAOYSA-N 0.000 claims 1
- VCUKMSHUJDBTKR-UHFFFAOYSA-N 4-(4-chloroanilino)-6-(dimethylamino)pyrimidine-2-carbonitrile Chemical compound N#CC1=NC(N(C)C)=CC(NC=2C=CC(Cl)=CC=2)=N1 VCUKMSHUJDBTKR-UHFFFAOYSA-N 0.000 claims 1
- CFTYWZFVQURLDD-UHFFFAOYSA-N 4-(4-chloroanilino)-6-(ethylamino)-1,3,5-triazine-2-carbonitrile Chemical compound N#CC1=NC(NCC)=NC(NC=2C=CC(Cl)=CC=2)=N1 CFTYWZFVQURLDD-UHFFFAOYSA-N 0.000 claims 1
- VSBXRTMJVIITDW-UHFFFAOYSA-N 4-(4-chloroanilino)-6-[4-[3-(dimethylamino)propyl]piperazin-1-yl]-5-methoxypyrimidine-2-carbonitrile Chemical compound N1=C(C#N)N=C(N2CCN(CCCN(C)C)CC2)C(OC)=C1NC1=CC=C(Cl)C=C1 VSBXRTMJVIITDW-UHFFFAOYSA-N 0.000 claims 1
- GKWVLGLOAVNKNN-UHFFFAOYSA-N 4-(4-chloroanilino)-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC1=NC(C#N)=NC(N2CCOCC2)=N1 GKWVLGLOAVNKNN-UHFFFAOYSA-N 0.000 claims 1
- ARIOMJSONVMVHM-UHFFFAOYSA-N 4-(4-chloroanilino)-6-morpholin-4-ylpyrimidine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC1=CC(N2CCOCC2)=NC(C#N)=N1 ARIOMJSONVMVHM-UHFFFAOYSA-N 0.000 claims 1
- PHRFVDJKWANIIJ-UHFFFAOYSA-N 4-(4-chloroanilino)-6-piperazin-1-ylpyrimidine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC1=CC(N2CCNCC2)=NC(C#N)=N1 PHRFVDJKWANIIJ-UHFFFAOYSA-N 0.000 claims 1
- XUABEUVVOXVCEQ-UHFFFAOYSA-N 4-(4-chloroanilino)-6-piperidin-1-yl-1,3,5-triazine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC1=NC(C#N)=NC(N2CCCCC2)=N1 XUABEUVVOXVCEQ-UHFFFAOYSA-N 0.000 claims 1
- FNIDFZPHGCXTQD-UHFFFAOYSA-N 4-(4-chloroanilino)-6-pyrrolidin-1-yl-1,3,5-triazine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC1=NC(C#N)=NC(N2CCCC2)=N1 FNIDFZPHGCXTQD-UHFFFAOYSA-N 0.000 claims 1
- JBJHOQKLHPKKNE-UHFFFAOYSA-N 4-(4-chloroanilino)-6-pyrrolidin-1-ylpyrimidine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC1=CC(N2CCCC2)=NC(C#N)=N1 JBJHOQKLHPKKNE-UHFFFAOYSA-N 0.000 claims 1
- RCCAPSQQOVDJIJ-UHFFFAOYSA-N 4-(4-chlorophenoxy)-6-morpholin-4-ylpyrimidine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1OC1=CC(N2CCOCC2)=NC(C#N)=N1 RCCAPSQQOVDJIJ-UHFFFAOYSA-N 0.000 claims 1
- ICWNIFGBCIVBTL-UHFFFAOYSA-N 4-(4-imidazol-1-ylpiperidin-1-yl)-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile Chemical compound N=1C(C#N)=NC(N2CCOCC2)=NC=1N(CC1)CCC1N1C=CN=C1 ICWNIFGBCIVBTL-UHFFFAOYSA-N 0.000 claims 1
- NLPJWWPRAXCQIW-UHFFFAOYSA-N 4-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(4-chloroanilino)-1,3,5-triazine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC1=NC(C#N)=NC(N2C3CCC2CC3)=N1 NLPJWWPRAXCQIW-UHFFFAOYSA-N 0.000 claims 1
- ZOZJTLLDGHUBPY-UHFFFAOYSA-N 4-(azetidin-1-yl)-6-(4-chloroanilino)-1,3,5-triazine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC1=NC(C#N)=NC(N2CCC2)=N1 ZOZJTLLDGHUBPY-UHFFFAOYSA-N 0.000 claims 1
- JACOZRXEUWTVOP-UHFFFAOYSA-N 4-(cyclohexylamino)-6-morpholin-4-ylpyrimidine-2-carbonitrile Chemical compound C=1C(N2CCOCC2)=NC(C#N)=NC=1NC1CCCCC1 JACOZRXEUWTVOP-UHFFFAOYSA-N 0.000 claims 1
- SWHVKIKRWPLXPK-UHFFFAOYSA-N 4-[(1-methylpiperidin-4-yl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile Chemical compound C1CN(C)CCC1NC1=CC(N2CCOCC2)=NC(C#N)=N1 SWHVKIKRWPLXPK-UHFFFAOYSA-N 0.000 claims 1
- WOXKHFVEAVYTRX-UHFFFAOYSA-N 4-[(3-chlorophenyl)methylamino]-6-(dimethylamino)-1,3,5-triazine-2-carbonitrile Chemical compound N#CC1=NC(N(C)C)=NC(NCC=2C=C(Cl)C=CC=2)=N1 WOXKHFVEAVYTRX-UHFFFAOYSA-N 0.000 claims 1
- KJLDVJFLNOBWQC-NSHDSACASA-N 4-[(3s)-3-aminopyrrolidin-1-yl]-6-(4-chloroanilino)-5-methoxypyrimidine-2-carbonitrile Chemical compound N1=C(C#N)N=C(N2C[C@@H](N)CC2)C(OC)=C1NC1=CC=C(Cl)C=C1 KJLDVJFLNOBWQC-NSHDSACASA-N 0.000 claims 1
- QTUPPQQZNILLGV-UHFFFAOYSA-N 4-[(4-methylcyclohexyl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile Chemical compound C1CC(C)CCC1NC1=CC(N2CCOCC2)=NC(C#N)=N1 QTUPPQQZNILLGV-UHFFFAOYSA-N 0.000 claims 1
- FBBDIKHSVMXWNJ-UHFFFAOYSA-N 4-[(6-chloropyridin-3-yl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile Chemical compound C1=NC(Cl)=CC=C1NC1=CC(N2CCOCC2)=NC(C#N)=N1 FBBDIKHSVMXWNJ-UHFFFAOYSA-N 0.000 claims 1
- HKYNATOIQKWVMA-UHFFFAOYSA-N 4-[2-(furan-2-yl)ethylamino]-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile Chemical compound N=1C(N2CCOCC2)=NC(C#N)=NC=1NCCC1=CC=CO1 HKYNATOIQKWVMA-UHFFFAOYSA-N 0.000 claims 1
- AGZVGTBMPVFJME-UHFFFAOYSA-N 4-[4-(2-methoxyphenyl)piperazin-1-yl]-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile Chemical compound COC1=CC=CC=C1N1CCN(C=2N=C(N=C(N=2)C#N)N2CCOCC2)CC1 AGZVGTBMPVFJME-UHFFFAOYSA-N 0.000 claims 1
- QBVCDJOMJPOECH-UHFFFAOYSA-N 4-[4-(4-chlorobenzoyl)piperidin-1-yl]-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(=O)C1CCN(C=2N=C(N=C(N=2)C#N)N2CCOCC2)CC1 QBVCDJOMJPOECH-UHFFFAOYSA-N 0.000 claims 1
- NSXYUBSJTLTVOX-UHFFFAOYSA-N 4-[4-(5-chloropyridin-2-yl)piperazin-1-yl]-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile Chemical compound N1=CC(Cl)=CC=C1N1CCN(C=2N=C(N=C(N=2)C#N)N2CCOCC2)CC1 NSXYUBSJTLTVOX-UHFFFAOYSA-N 0.000 claims 1
- VVFZSWNCOHTYQS-UHFFFAOYSA-N 4-morpholin-4-yl-6-(2-pyridin-3-ylethylamino)-1,3,5-triazine-2-carbonitrile Chemical compound N=1C(N2CCOCC2)=NC(C#N)=NC=1NCCC1=CC=CN=C1 VVFZSWNCOHTYQS-UHFFFAOYSA-N 0.000 claims 1
- ACPGGAROWYBYCA-UHFFFAOYSA-N 4-morpholin-4-yl-6-(3-phenylpiperidin-1-yl)-1,3,5-triazine-2-carbonitrile Chemical compound N=1C(C#N)=NC(N2CCOCC2)=NC=1N(C1)CCCC1C1=CC=CC=C1 ACPGGAROWYBYCA-UHFFFAOYSA-N 0.000 claims 1
- RSBVTQNOBXLYGL-UHFFFAOYSA-N 4-morpholin-4-yl-6-(4-morpholin-4-ylanilino)-1,3,5-triazine-2-carbonitrile Chemical compound N=1C(N2CCOCC2)=NC(C#N)=NC=1NC(C=C1)=CC=C1N1CCOCC1 RSBVTQNOBXLYGL-UHFFFAOYSA-N 0.000 claims 1
- KHPHMGJSXDODOC-UHFFFAOYSA-N 4-morpholin-4-yl-6-(4-phenoxypiperidin-1-yl)-1,3,5-triazine-2-carbonitrile Chemical compound N=1C(C#N)=NC(N2CCOCC2)=NC=1N(CC1)CCC1OC1=CC=CC=C1 KHPHMGJSXDODOC-UHFFFAOYSA-N 0.000 claims 1
- URMHHFDWPPZHIV-UHFFFAOYSA-N 4-morpholin-4-yl-6-(4-piperidin-1-ylpiperidin-1-yl)-1,3,5-triazine-2-carbonitrile Chemical compound N=1C(C#N)=NC(N2CCOCC2)=NC=1N(CC1)CCC1N1CCCCC1 URMHHFDWPPZHIV-UHFFFAOYSA-N 0.000 claims 1
- JORNRTNWRASXHW-UHFFFAOYSA-N 4-morpholin-4-yl-6-[3-(2-oxopyrrolidin-1-yl)propylamino]-1,3,5-triazine-2-carbonitrile Chemical compound O=C1CCCN1CCCNC1=NC(C#N)=NC(N2CCOCC2)=N1 JORNRTNWRASXHW-UHFFFAOYSA-N 0.000 claims 1
- HLVUUIRENGTYML-UHFFFAOYSA-N 5-amino-4-(4-chloroanilino)-6-(ethylamino)pyrimidine-2-carbonitrile Chemical compound CCNC1=NC(C#N)=NC(NC=2C=CC(Cl)=CC=2)=C1N HLVUUIRENGTYML-UHFFFAOYSA-N 0.000 claims 1
- GJHNZJNXSKYROP-UHFFFAOYSA-N 5-amino-4-(4-chloroanilino)-6-morpholin-4-ylpyrimidine-2-carbonitrile Chemical compound N1=C(C#N)N=C(N2CCOCC2)C(N)=C1NC1=CC=C(Cl)C=C1 GJHNZJNXSKYROP-UHFFFAOYSA-N 0.000 claims 1
- JLEVFFZEGQVAOR-UHFFFAOYSA-N 5-chloro-4-(4-chloroanilino)-6-morpholin-4-ylpyrimidine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC1=NC(C#N)=NC(N2CCOCC2)=C1Cl JLEVFFZEGQVAOR-UHFFFAOYSA-N 0.000 claims 1
- HXDJGRYZPYELDQ-UHFFFAOYSA-N C(#N)C1=NC(=NC(=N1)N1CCOCC1)N(CC(=O)N1C(COCC1)NCC(=O)NC(C)(C)C)CC(C)C Chemical compound C(#N)C1=NC(=NC(=N1)N1CCOCC1)N(CC(=O)N1C(COCC1)NCC(=O)NC(C)(C)C)CC(C)C HXDJGRYZPYELDQ-UHFFFAOYSA-N 0.000 claims 1
- 108010005843 Cysteine Proteases Proteins 0.000 claims 1
- 102000005927 Cysteine Proteases Human genes 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 claims 1
- 150000002780 morpholines Chemical class 0.000 claims 1
- 125000004193 piperazinyl group Chemical class 0.000 claims 1
- IIHQNAXFIODVDU-UHFFFAOYSA-N pyrimidine-2-carbonitrile Chemical compound N#CC1=NC=CC=N1 IIHQNAXFIODVDU-UHFFFAOYSA-N 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000001174 sulfone group Chemical group 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- ULQQGOGMQRGFFR-UHFFFAOYSA-N 2-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=CC=C1Cl ULQQGOGMQRGFFR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201976A SE0201976D0 (sv) | 2002-06-24 | 2002-06-24 | Novel compounds |
| PCT/SE2003/001078 WO2004000819A1 (en) | 2002-06-24 | 2003-06-23 | New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005533803A JP2005533803A (ja) | 2005-11-10 |
| JP2005533803A5 true JP2005533803A5 (enExample) | 2006-08-17 |
Family
ID=20288334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004515328A Pending JP2005533803A (ja) | 2002-06-24 | 2003-06-23 | システインプロテアーゼ活性と関連する疾患の処置のためのピリミジン−またはトリアジン−２−カルボニトリルの新規使用および新規ピリミジン−２−カルボニトリル誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7125881B2 (enExample) |
| EP (1) | EP1532121B1 (enExample) |
| JP (1) | JP2005533803A (enExample) |
| AT (1) | ATE353880T1 (enExample) |
| AU (1) | AU2003243095A1 (enExample) |
| DE (1) | DE60311820T2 (enExample) |
| ES (1) | ES2280794T3 (enExample) |
| SE (1) | SE0201976D0 (enExample) |
| WO (1) | WO2004000819A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| SE0201980D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| GB0220187D0 (en) | 2002-08-30 | 2002-10-09 | Novartis Ag | Organic compounds |
| RS20050532A (sr) * | 2003-01-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija |
| SI1599468T1 (sl) | 2003-01-14 | 2008-02-29 | Arena Pharm Inc | 1,2,3-trisubstituirani arilni in heteroarilni derivati kot modulatorji metabolizma ter profilaksa in zdravljenje motenj v zvezi z njim, kot diabetesain hiperglikemije |
| US20040242568A1 (en) | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| KR20060056944A (ko) | 2003-07-14 | 2006-05-25 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료 |
| MXPA06001601A (es) | 2003-08-13 | 2006-08-25 | Takeda Pharmaceutical | Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa. |
| WO2005026148A1 (en) * | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| JP2007522233A (ja) | 2004-02-11 | 2007-08-09 | アムジエン・インコーポレーテツド | バニロイド受容体リガンド及び治療におけるそれらの使用 |
| CN102079743B (zh) | 2004-03-15 | 2020-08-25 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| TW200614993A (en) * | 2004-06-11 | 2006-05-16 | Akzo Nobel Nv | 4-phenyl-pyrimidine-2-carbonitrile derivatives |
| GB0418353D0 (en) * | 2004-08-17 | 2004-09-22 | Novartis Ag | Organic compounds |
| JP4958787B2 (ja) | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体 |
| WO2006040300A1 (en) * | 2004-10-12 | 2006-04-20 | N.V. Organon | 4-cycloalkyl-pyrimidine-2-carbonitrile derivatives |
| JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| GB0514684D0 (en) * | 2005-07-18 | 2005-08-24 | Novartis Ag | Organic compounds |
| NZ566799A (en) | 2005-09-14 | 2011-04-29 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
| WO2007035629A2 (en) | 2005-09-16 | 2007-03-29 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
| TW200745055A (en) * | 2005-09-23 | 2007-12-16 | Organon Nv | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| US7326715B2 (en) | 2005-09-23 | 2008-02-05 | N.V. Organon | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| US7687515B2 (en) | 2006-01-17 | 2010-03-30 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| US8324383B2 (en) * | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| PL2073810T3 (pl) * | 2006-09-13 | 2012-01-31 | Takeda Pharmaceuticals Co | Zastosowanie 2-6-(3-amino-piperydyn-1-ylo)-3-metylo-2,4-diokso-3,4-dihydro-2H-pirymidyn-1-ylometylo-4-fluoro-benzonitrylu do leczenia cukrzycy, raka, zaburzeń autoimmunizacyjnych i zakażeń HIV |
| US20080200454A1 (en) * | 2007-02-15 | 2008-08-21 | Ameriks Michael K | Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US20090099157A1 (en) * | 2007-02-15 | 2009-04-16 | Ameriks Michael K | Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s |
| US20080269241A1 (en) * | 2007-02-15 | 2008-10-30 | Darin Allen | Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US20090118274A1 (en) * | 2007-02-15 | 2009-05-07 | Darin Allen | Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US20080207683A1 (en) * | 2007-02-15 | 2008-08-28 | Darin Allen | Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US8093236B2 (en) * | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| US7932251B2 (en) | 2007-07-16 | 2011-04-26 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| US20100144140A1 (en) * | 2008-12-10 | 2010-06-10 | Novellus Systems, Inc. | Methods for depositing tungsten films having low resistivity for gapfill applications |
| TW201035094A (en) | 2009-01-16 | 2010-10-01 | Organon Nv | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| US8026236B2 (en) | 2009-01-16 | 2011-09-27 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| EP2523954B1 (en) | 2010-01-15 | 2014-04-16 | Merck Sharp & Dohme B.V. | 1h-[1,2,3]triazolo[4,5-c]pyridine-4- carbonitrile derivatives as cathepsin s inhibitors |
| CN103221410B (zh) | 2010-09-22 | 2017-09-15 | 艾尼纳制药公司 | Gpr119受体调节剂和对与其相关的障碍的治疗 |
| US8524710B2 (en) * | 2010-11-05 | 2013-09-03 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives |
| CA3002540C (en) | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩 |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| JP7397011B2 (ja) | 2018-06-06 | 2023-12-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１ｐ１受容体に関連する状態を治療する方法 |
| AU2020250933A1 (en) | 2019-04-05 | 2021-10-28 | Centre Hospitalier Régional Et Universitaire De Brest | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE870304C (de) * | 1951-05-08 | 1953-03-12 | Bayer Ag | Verfahren zur Herstellung von Azofarbstoffen |
| NL270922A (enExample) * | 1960-11-02 | |||
| DE1172684B (de) * | 1962-09-15 | 1964-06-25 | Degussa | Verfahren zur Herstellung von substituierten 2, 4-Bis-alkylamino-1, 3, 5-triazinverbindungen |
| DE1182667B (de) * | 1963-04-13 | 1964-12-03 | Degussa | Verfahren zur Herstellung von s-Triazinverbindungen |
| NL284584A (enExample) * | 1962-11-22 | |||
| US3553326A (en) * | 1968-04-17 | 1971-01-05 | Shell Oil Co | Use of 2-(cyanoalkyl)amino-4-amino-6-substituted-s-triazines for inducing depressant effects in animals |
| BR6915234D0 (pt) * | 1969-05-22 | 1973-06-07 | American Cyanamid Co | Novos derivados de melamina e processo para sua preparaca |
| CH627919A5 (de) * | 1977-04-14 | 1982-02-15 | Ciba Geigy Ag | Herbizide mittel. |
| JPS58206572A (ja) * | 1982-05-12 | 1983-12-01 | イ−・アイ・デユポン・デ・ニモアス・アンド・カンパニ− | 複素環式アルキルアミノカルボニルスルホンアミド |
| HU212435B (en) * | 1990-06-07 | 1996-06-28 | Sandoz Ag | Herbicidal compositions containing substituted phthalides and heterocyclic phthalides as active ingredient and process for preparation of their active ingredients. |
| JP3213775B2 (ja) * | 1992-10-30 | 2001-10-02 | イハラケミカル工業株式会社 | ２−シアノ−４，６−ジメトキシピリミジンの製造方法 |
| WO1994027974A1 (en) * | 1993-05-27 | 1994-12-08 | Shell Internationale Research Maatschappij B.V. | Herbicidal compounds |
| JP3013752B2 (ja) * | 1995-05-16 | 2000-02-28 | 田辺製薬株式会社 | スルホンアミド誘導体 |
| JPH11512399A (ja) | 1995-09-01 | 1999-10-26 | シグナル ファーマシューティカルズ，インコーポレイテッド | ピリミジンカルボキサミドおよび関連化合物ならびに炎症状態を処置するための方法 |
| JPH10226649A (ja) * | 1996-12-12 | 1998-08-25 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| EA200100972A1 (ru) | 1999-03-15 | 2002-02-28 | Аксис Фармасьютикалз, Инк. | Новые соединения и композиции как ингибиторы протеаз |
| WO2001081338A1 (en) * | 2000-04-25 | 2001-11-01 | Actelion Pharmaceuticals Ltd | Substituted sulfonylaminopyrimidines |
| CA2406562C (en) * | 2000-05-08 | 2009-09-15 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines and triazines |
| WO2002032879A1 (en) | 2000-10-19 | 2002-04-25 | Naeja Pharmaceutical Inc. | Dihydropyrimidine derivatives as cysteine protease inhibitors |
| DE10111649A1 (de) * | 2001-03-12 | 2002-09-19 | Bayer Ag | Substituierte Fluoralkoxyphenylsulfonylharnstoffe |
| AR036375A1 (es) * | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
-
2002
- 2002-06-24 SE SE0201976A patent/SE0201976D0/xx unknown
-
2003
- 2003-06-23 US US10/518,817 patent/US7125881B2/en not_active Expired - Fee Related
- 2003-06-23 JP JP2004515328A patent/JP2005533803A/ja active Pending
- 2003-06-23 AT AT03761001T patent/ATE353880T1/de not_active IP Right Cessation
- 2003-06-23 EP EP03761001A patent/EP1532121B1/en not_active Expired - Lifetime
- 2003-06-23 ES ES03761001T patent/ES2280794T3/es not_active Expired - Lifetime
- 2003-06-23 WO PCT/SE2003/001078 patent/WO2004000819A1/en not_active Ceased
- 2003-06-23 AU AU2003243095A patent/AU2003243095A1/en not_active Abandoned
- 2003-06-23 DE DE60311820T patent/DE60311820T2/de not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7125881B2 (en) | Use of pyrimidine—or triazine—2 carbonitiles for treating diseases associated with cysteine prostease activity and novel pyrimidine-2-carbonitile derivatives | |
| ES2316575T3 (es) | Derivado de fenilpiridincarbonilpiperazina. | |
| TWI699359B (zh) | ４ｈ-吡咯［３,２-ｃ］吡啶-４-酮衍生物 | |
| US9855269B2 (en) | Aminoquinazoline and pyridopyrimidine derivatives | |
| RU2004125146A (ru) | Новые соединения | |
| PT2516009E (pt) | Isoquinolinonas e quinazolinonas substituídas | |
| JP2024517750A (ja) | 化合物及びそれらのｃｄ３８阻害剤としての使用 | |
| KR101983585B1 (ko) | Hec1 활성의 개선된 조절인자 및 이를 위한 방법 | |
| JP2011515462A5 (enExample) | ||
| WO2003000660A1 (fr) | Derive de quinoleine et derive de quinoleine permettant d'inhiber l'auto-phosphorylation du recepteur des proliferateurs des hepatocytes, ainsi que des compositions medicinales contenant ce derive | |
| JP2004203871A (ja) | 医薬組成物 | |
| ES2799300T3 (es) | Compuestos heteroarilo y su uso como fármacos terapéuticos | |
| RU2005103618A (ru) | Ингибирующие циклооксигеназу-2 (цог-2) производные пиридина | |
| JP5892550B2 (ja) | 縮合イミダゾール誘導体 | |
| RU2149872C1 (ru) | Пиридилтиосоединения для борьбы с бактериями helicobacter | |
| JP4186518B2 (ja) | フェニルピリジン誘導体 | |
| JPWO2004094407A1 (ja) | ５員複素環誘導体 | |
| JP7763538B2 (ja) | Ｐａｒｐ７阻害剤及びその使用 | |
| JPH02184673A (ja) | スルホンアミド化合物 | |
| US6391880B1 (en) | Heterocyclic compounds useful as oxido-squalene cyclase inhibitors | |
| JP3916092B2 (ja) | イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬 | |
| JP7144863B2 (ja) | イソキノリン化合物、その調製の方法、およびベータガラクトシダーゼの活性の変質に伴う状態におけるその治療的使用 | |
| RU2135492C1 (ru) | Замещенные аминоалкиламинопиридины и лекарственное средство на их основе | |
| GB2162843A (en) | Piperazine derivatives | |
| JPS62169779A (ja) | ジヒドロピリジン系の抗虚血薬および降圧薬 |